C-MET agonistic antibody and use thereof
A method for treating or preventing vascular endothelial cell injured diseases, especially cerebral infarctions or myocardial infarctions, by administering a c-MET agonist antibody to a subject in need thereof, and specific c-MET agonist antibodies.
1. An antibody or functional fragment thereof capable of binding to c-MET, comprising a heavy chain and a light chain, wherein:
the heavy chain comprises a heavy chain variable region which comprises a CDR1 of SEQ ID NO: 9, a CDR2 of SEQ ID NO: 10, and a CDR3 of SEQ ID NO: 11, and
the light chain comprises a light chain variable region which comprises a CDR1 of SEQ ID NO: 12, a CDR2 of SEQ ID NO: 13, and a CDR3 of SEQ ID NO: 14.
2. A pharmaceutical composition comprising the antibody or functional fragment thereof according to claim 1 , and a pharmaceutically acceptable carrier.
3. The pharmaceutical composition according claim 2 , further comprising one or more pharmaceutically active compounds for treatment or prevention of a disease caused by vascular endothelial cell injury.
4. The pharmaceutical composition according to claim 2 , further comprising an IRF5 inhibitor, paclitaxel, a lipid-lowering drug, or an angiogenesis inhibitor, or a combination thereof.
5. A method for treatment of an ischemic disease caused by vascular endothelial cell injury comprising administering to a subject in need thereof a therapeutically effective amount of a c-MET agonist antibody or functional fragment thereof according to claim 1 to reduce apoptosis of vascular endothelial cells.
6. The method according to claim 5 , wherein the ischemic disease is cerebral infarction or myocardial infarction.